Governance Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-16 EST			After hours 16:30:00
118.78 ^USD	-0.83%		118.00	-0.66%

12-15	RedHill Biopharma Ltd.'s Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells	CI
12-15	Gilead HIV combo of bictegravir & lenacapavir hits phase 3 goal	RE

Executive Committee: Gilead Sciences, Inc.

Manager

Positions heldSince

Daniel O'Day

60 year

Chief Executive Officer

2019-02-28

Dietmar Berger

63 year

Chief Tech/Sci/R&D Officer

2025-01-01

Sarah Miksinski

General Counsel

Jacquie Ross

Investor Relations Contact

2020-12-31

Jyoti Mehra

49 year

Human Resources Officer

2017-10-31

Andrew Dickinson

55 year

Director of Finance/CFO

2019-10-31

Erin Burkhart

56 year

Comptroller/Controller/Auditor

2025-09-21

Composition of the Board of Directors: Gilead Sciences, Inc.

Director

CommitteesSince

Daniel O'Day

60 year

Chairman

2019-02-28

Kelly Kramer

57 year

Compensation Committee	2021-11-30
HR Committee
Audit Committee Chair	2020-11-30
Audit Committee	2021-11-30
Governance Committee	2020-01-31
Nominating Committee	2020-01-31

Harish M. Manwani

71 year

HR Committee	2018-05-08
Governance Committee	2011-08-16
Nominating Committee	2021-05-11
Compensation Committee	2018-05-08
Governance Committee Chair	2021-05-11

Anthony Welters

70 year

Governance Committee	2021-05-11
Nominating Committee	2021-05-11
Compensation Committee Chair	2020-10-16
HR Committee	2020-10-16

Ted Love

66 year

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	2023-08-02
Audit Committee	2025-11-30

Sandra Horning

76 year

Governance Committee	2020-11-12
Nominating Committee	2020-11-12

Jacqueline Barton

72 year

Compensation Committee	2017-12-31
HR Committee	2017-12-31

Javier Rodriguez

54 year

Audit Committee

2020-06-14

Jeffrey Bluestone

71 year

Executive Committee

2020-04-08

Latest Appointments: Gilead Sciences, Inc.

12-03	Soleno Therapeutics, Inc. Announces Demise of William G. Harris, Member of Board of Directors and Audit Committee Changes	CI
11-26	Vera Therapeutics, Inc. Appoints James R. Meyers to Its Board of Directors	CI
11-19	Gilead says Deborah Telman to step down as evp at Gilead Sciences - SEC filing	RE
11-19	Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025	CI
11-14	Cytokinetics, Incorporated Appoints Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, Effective as of November 14, 2025	CI
11-10	Nurix Therapeutics, Inc. Appoints Roger Dansey to Its Board of Directors	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI

More news

Former Officers and Directors: Gilead Sciences, Inc.

Insider

Positions held

SinceUntil

Kevin Lofton

Director/Board Member	2009-07-28	2024-05-07
Independent Dir/Board Member	2009-07-28	2024-05-07

Brett Pletcher

Compliance Officer	-	2022-07-31
General Counsel	2011-03-30	2022-07-31
Corporate Officer/Principal	2004-12-31	2011-03-30
Corporate Secretary	-	2022-07-31

Tai Yin Yang

Corporate Officer/Principal

2004-12-31

2022-07-17

Amy E. Flood

Public Communications Contact

2021-05-31

William Lee

Chief Tech/Sci/R&D Officer

1990-12-31

2021-04-11

Richard Whitley

Director/Board Member	2008-06-30	2020-12-31
Independent Dir/Board Member	2008-06-30	2020-12-31

Robin Washington

Comptroller/Controller/Auditor	2008-05-04	2019-10-31
Director of Finance/CFO	2008-05-04	2019-10-31

Gregg Alton

Chief Executive Officer	2018-12-31	2019-02-28
Compliance Officer	1998-12-31	-
Public Communications Contact	2009-08-03	2012-05-08
General Counsel	1998-12-31	2009-08-03
Corporate Officer/Principal	2019-02-28	2019-10-03
Corporate Secretary	1998-12-31	-

John McHutchison

Chief Tech/Sci/R&D Officer	2018-02-28	2019-08-01
Corporate Officer/Principal	2010-06-07	2018-02-28

John Martin

Chief Executive Officer	1995-12-31	2016-03-09
Chairman	2008-05-31	2019-02-28

John Milligan

Director/Board Member	2016-01-27	2018-12-30
Chief Executive Officer	2016-03-09	2018-12-30
Chief Operating Officer	2006-12-31	2016-03-09
Director of Finance/CFO	2001-12-31	2006-12-31
President	2007-12-31	2018-12-30

Andrew Cheng

Chief Tech/Sci/R&D Officer	-	2018-09-06
Corporate Officer/Principal	1998-12-31	-

Norbert W. Bischofberger

Chief Tech/Sci/R&D Officer	1994-12-31	2018-04-29
Corporate Officer/Principal	1990-07-31	1994-12-31

James Meyers

Corporate Officer/Principal

1995-12-31

2018-02-21

John Madigan

Director/Board Member	2005-11-30	2017-05-09
Independent Dir/Board Member	2011-07-21	2017-05-09

Paul Carter

Corporate Officer/Principal

2006-03-31

2016-07-31

Kevin B. Young

Corporate Officer/Principal	2004-08-31	2014-02-03
Chief Operating Officer	2016-05-23	-

Gordon Earle Moore

Director/Board Member	1995-12-31	2013-05-30
Independent Dir/Board Member	2011-07-21	2013-05-30

James M. Denny

Director/Board Member	1995-12-31	2013-05-30
Independent Dir/Board Member	2011-07-21	2013-05-30

Susan T. Hubbard

Investor Relations Contact

1989-08-31

2012-05-31

Alan Montgomery

Corporate Officer/Principal

2006-07-31

2011-04-30

Anthony D. Caracciolo

Corporate Officer/Principal

1996-12-31

2010-09-30

Per Wold-Olsen

Director/Board Member	2010-01-27	-
Independent Dir/Board Member	2010-01-27	-

Louis Lange

Corporate Officer/Principal

2009-04-19

Seigo Izumo

Corporate Officer/Principal

2008-08-31

Caroline Dorsa

Director of Finance/CFO

2007-11-04

2008-01-16

Howard Rosen

Corporate Officer/Principal

2003-12-31

2007-12-31

Carla A. Hills

Director/Board Member	2006-12-31	-
Independent Dir/Board Member	2011-07-21	-

Kristen M. Metza

Human Resources Officer

2005-12-31

Steven Fife

Comptroller/Controller/Auditor

2004-12-31

2005-12-31

John Francis Cogan

Director/Board Member	2005-06-30	-
Independent Dir/Board Member	2005-06-30	-

Nicholas G. Moore

Director/Board Member	2004-02-29	-
Independent Dir/Board Member	2004-02-29	-

Karl G. Trass

General Counsel

2002-12-31

2003-06-30

James Sapirstein

Sales & Marketing

2000-05-31

2002-05-31

Rebecca Coleman

Director/Board Member

2000-01-01

Michael W. Aguiar

Director of Finance/CFO

2001-12-31

Robert L. Simon

General Counsel

2000-06-30

2001-11-30

Gayle Edlund Wilson

Director/Board Member	2001-09-30	-
Independent Dir/Board Member	2001-09-30	-

Jeff Bird

Corporate Officer/Principal

1999-12-31

Kenneth Cundy

Corporate Officer/Principal

1991-12-31

1999-12-31

Mark D. Matteucci

Corporate Officer/Principal

1987-12-31

1998-12-31

Louis C. Bock

Corporate Officer/Principal

1989-08-31

Robert J. Stagg

Chief Tech/Sci/R&D Officer

1993-07-31

1996-11-30

Bill Harris

Director of Finance/CFO

1989-12-31

1995-12-31

Michael Bigham

Chief Operating Officer	1987-12-31	1995-12-31
Director of Finance/CFO	1987-12-31	1995-12-31

George Pratt Shultz

Director/Board Member

1995-12-31

John Latham

Corporate Officer/Principal

1988-12-31

1993-12-31

Étienne Francois Davignon

Director/Board Member	1990-08-31	-
Independent Dir/Board Member	2011-07-21	-

John J. Toole

Corporate Officer/Principal

1990-03-31

Akram Bouchenaki

Corporate Officer/Principal

Nicholas S. Hellmann

Corporate Officer/Principal

Joseph M. Baini

Corporate Officer/Principal

Wenjin Yang

Corporate Officer/Principal

James V. Desiderio

Corporate Officer/Principal

Jim Ziegler

Corporate Officer/Principal	-	-
Sales & Marketing	-	-

George Tidmarsh

Corporate Officer/Principal

Erin Edgley

Public Communications Contact

Patrick O'Brien

Investor Relations Contact

Sunil Patel

Corporate Officer/Principal

Dirk B. Mendel

Corporate Officer/Principal

Jeffrey Rudy

Corporate Officer/Principal

Gulshan H. Shaver

Corporate Officer/Principal

Gary C. Visor

Corporate Officer/Principal

Roger G. Mills

Corporate Officer/Principal

Julie Cherrington

Corporate Officer/Principal

Cordell W. Hull

Director/Board Member

David Brogan

Corporate Officer/Principal

Jeffery P. Davis

Corporate Officer/Principal

Mark Italia

General Counsel

Richard J. Gorczynski

Corporate Officer/Principal

Pamela Goss

Corporate Officer/Principal

Adam Tomasi

Corporate Officer/Principal

Robert L. St. Claire

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	19
Female	8

Of which Executive Committee

Male	4
Female	3

Of which Directors

Male	8
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

02-09 - Q4 2025 Earnings Release (Projected)

More about the company